Business Context and Reporting Period
This Form 8-K Current Report was filed by Athira Pharma, Inc. (trading symbol: ATHA) on May 22, 2023, covering events occurring on May 18, 2023. The filing details significant executive leadership changes, the results of the 2023 Annual Meeting of Stockholders, and updates to Board committee compositions. Note: The request metadata referenced "Leonabio, Inc.," but the filing text explicitly identifies the registrant as Athira Pharma, Inc.
Key Financial Metrics and Compensation
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or debt levels. However, it discloses specific compensation terms for the newly appointed Chief Financial Officer (CFO) and Chief Business Officer:
- Base Salary: $465,000 annually for Andrew Gengos.
- Performance Bonus: Up to 40% of base salary, prorated for 2023.
- Equity Grants: 10,000 Restricted Stock Units (RSUs) tied to clinical trial milestones and an option to purchase 400,000 shares.
- Severance: Lump-sum payments ranging from 75% to 100% of base salary and bonus depending on termination timing relative to a change in control.
- Outgoing CFO Transition: Glenna Mileson will receive a monthly consulting fee of $3,500 for up to 10 hours per month post-transition.
Material Changes Versus Prior Period
The primary material changes reported are personnel and governance shifts effective May 18, 2023:
- Executive Departure: Glenna Mileson resigned as Chief Financial Officer effective immediately.
- Executive Appointment: Andrew Gengos was appointed as Chief Financial Officer and Chief Business Officer effective immediately.
- Board Committee Restructuring:
- Audit Committee: Grant Pickering appointed; Kelly Romano stepped down.
- Nominating Committee: Kelly Romano appointed as Chairperson; Michael Panzara appointed as member; John Fluke stepped down.
- Compensation Committee: Joseph Edelman stepped down.
Guidance, Outlook, and Voting Results
The filing does not provide financial guidance or operational outlook beyond the standard business context of a clinical-stage biopharmaceutical company. Key governance outcomes from the Annual Meeting held on May 18, 2023, include:
- Attendance: 26,763,628 shares (approximately 70.5% of total shares entitled to vote) were present.
- Proposal 1 (Election of Directors): Both nominees, Kelly A. Romano and James A. Johnson, were elected.
- Kelly A. Romano: 13,993,414 For; 3,466,402 Withhold.
- James A. Johnson: 14,519,313 For; 2,940,503 Withhold.
- Proposal 2 (Auditor Ratification): Ernst & Young LLP was ratified.
- For: 26,704,561; Against: 39,131; Abstain: 19,936.
Important Facts for Investor Verification
- Verify the company name discrepancy: The filing is for Athira Pharma, Inc., not Leonabio, Inc.
- Confirm the vesting schedule for Andrew Gengos's 400,000 stock options, which includes a one-third cliff vesting on May 18, 2024, and monthly vesting thereafter.
- Review the specific milestones for the 10,000 RSUs granted to Mr. Gengos, which are tied to the enrollment and readout of the "LIFT" clinical trial.
- Note the significant number of broker non-votes (9,303,812) on the director election proposals, indicating shares held by brokers that did not receive voting instructions.
- Check the transition timeline for Glenna Mileson, who remains employed until June 16, 2023, before potentially moving to a consulting role.